uBriGene Biosciences, a prominent contract development and manufacturing organization (CDMO) known for its expertise in lentiviral vector production and Advanced Therapy Medicinal Product (ATMP) development, has announced a significant collaboration with Cellinfinity BIO. This biotechnology firm is focused on pioneering in vivo CAR-T therapies aimed at treating both hematologic and solid tumors.
This alliance is set to expedite the clinical progression of Cellinfinity BIO’s therapeutic candidates, CIB-301 and CIB-350. By utilizing its advanced LVV Turbo platform, uBriGene will provide efficient and cost-effective manufacturing of GMP-grade lentiviral vectors, encompassing process development, production, and regulatory assistance.
Exciting Collaborative Potential
Dr. Sun Xiulian, Co-founder and CTO of uBriGene, expressed enthusiasm about the partnership, highlighting the promise of in vivo CAR-T technologies to significantly reduce treatment expenses. He emphasized that their proprietary LVV Turbo platform, combined with their GMP manufacturing proficiency, aims to enhance accessibility and affordability of CAR-T therapies for patients.
In response, Dr. Chen Sidi, Founder of Cellinfinity BIO, acknowledged uBriGene’s substantial experience in plasmid and viral vector manufacturing, alongside their comprehensive global regulatory capabilities. He noted that the proprietary LVV Turbo platform and integrated CDMO services create a robust foundation to hasten the clinical development and scalability of their in vivo CAR-T initiatives.
The LVV Turbo Advantage
The LVV Turbo platform stands out for its integration of three pioneering technologies, which include a high-productivity 293TH suspension cell line, a fully closed downstream purification process, and the Ultra-T enhancer. This combination provides a pathway to achieve higher yield, increased potency, and reduced costs.
- High-Productivity 293TH Suspension Cell Line: This technology enhances transduction titers by a factor of five.
- Fully Closed Downstream Process: This method attains up to 80% recovery rates, ensuring maximum efficiency.
-
Ultra-T Enhancer: This component further boosts T-cell transduction titers by an additional five times.
uBriGene’s Expertise and Resources
Founded in 2015, uBriGene has established itself as a leader in the field of CDMO services specializing in ATMPs. The organization provides a comprehensive range of CDMO and contract research organization (CRO) services tailored for cell therapies, viral vectors, and RNA-based therapeutics. Their operations are bolstered by in-house quality control testing and regulatory IND filing support.
uBriGene boasts global GMP Centers of Excellence and proprietary platforms, including AAV-Turbo, LVV Turbo, Cell Product manufacturing, and iPSC reprogramming technologies. These resources empower biotech and pharmaceutical entities to expedite the development of cutting-edge therapies.
Innovations in CAR-T Therapy
Cellinfinity BIO is at the forefront of developing next-generation in vivo CAR-T therapies designed to tackle significant challenges associated with solid tumors. Their proprietary directed evolution and in vivo CAR platforms facilitate precise T cell modulation, enhancing persistence while minimizing the risk of cytokine release. Preclinical trials of their lead programs, targeting various solid tumors, have shown promising antitumor efficacy and a favorable safety profile.
CIB-301, one of Cellinfinity’s primary therapeutic candidates, is an in vivo CAR-T therapy engineered for solid tumors. It features a fully human CAR scFv designed to minimize off-target risks while effectively addressing tumor antigens linked to several cancers, including renal cell carcinoma, colorectal cancer, non-small cell lung cancer, ovarian cancer, and endometrial cancer.
CIB-350 represents another innovative approach, targeting hematologic malignancies and autoimmune disorders. This therapy incorporates a novel bispecific CAR design, allowing it to target two distinct B-cell antigens simultaneously.
Looking Ahead
The partnership between uBriGene and Cellinfinity BIO signifies a substantial step forward in the development of advanced CAR-T therapies. By combining their unique technological capabilities and expertise, both companies are poised to make a significant impact in the field of oncology.
As the landscape of cancer treatment continues to evolve, the collaboration stands to enhance patient outcomes through innovative therapies that are both effective and accessible.
Key Takeaways
- uBriGene and Cellinfinity BIO have formed a strategic partnership to accelerate in vivo CAR-T therapies.
-
The LVV Turbo platform offers high-efficiency lentiviral vector manufacturing.
-
CIB-301 and CIB-350 are promising therapeutic candidates targeting solid tumors and hematologic malignancies.
-
The collaboration aims to enhance patient access to advanced cancer treatments.
In conclusion, the partnership between uBriGene Biosciences and Cellinfinity BIO represents a promising advancement in the realm of CAR-T therapies. By leveraging their respective strengths, they aim to deliver innovative solutions that address critical challenges in cancer treatment, ultimately improving patient care and outcomes.
Read more → www.finanznachrichten.de